Phase II study of S-1 plus docetaxel as first-line treatment for elderly patients with advanced gastric cancer (OGSG0902)

Randomized, open-label, phase II study comparing five-weekly S-1 plus cisplatin (SP) with triweekly capecitabine plus cisplatin (XP) in chemotherapy-naïve patients with HER2 negative advanced gastric cancer (AGC) (HERBIS-4A / OGSG 1105)

Randomized phase II study to compare docetaxel plus S-1 with cisplatin plus S-1 in advanced gastric cancer without measurable lesions (HERBIS-3)

A dose-finding study for irinotecan, cisplatin, and S-1 (IPS) in patients with advanced gastric cancer (HERBIS-4B / OGSG 1106)

A multicenter phase II trial of perioperative capecitabine plus oxaliplatin for clinical stage III gastric cancer (OGSG1601)

An Intergroup phase III trial of Ramucirumab plus Irinotecan in Third or more line Beyond Progression after Ramucirumab for advanced Gastric Cancer (RINDBeRG trial)

Phase II study of preoperative radiotherapy combined with S-1 plus cisplatin in clinically resectable type 4 or large type 3 gastric cancer （OGSG1205）

Phase II study of capecitabine plus oxaliplatin in patients with gastric cancer resistant/intolerable to CDDP (OGSG1403)

Phase II study of panitumumab monotherapy in chemotherapy-naïve frail or elderly patients with unresectable, RAS wild type colorectal cancer （OGSG1602）

A phase II trial of low-dose nab-paclitaxel for patients with previously treated or recurrent advanced gastric cancer (OGSG1302)